Primary central nervous system lymphoma

Jennifer I. Stern, Jeffrey J. Raizer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Primary central nervous system lymphoma is a stage 1E non-Hodgkin's lymphoma confined to the nervous system. It is seen in immunocompetent and immunodeficient populations, the latter group associated with the Epstein-Barr virus. Primary central nervous system lymphoma can affect the brain, leptomeninges, spinal cord or eyes. The institution of high-dose methotrexate-based regimens and whole-brain radiation therapy has significantly increased survival, but neurotoxicity is high in patients over 60 years of age. Despite these advances, 50% of patients initially treated will relapse. Recent investigations include the use of rituximab (immunotherapy) and stem-cell transplantation, as well as regimens without whole-brain radiation therapy in the elderly. The optimal treatment regimen is yet to been determined.

Original languageEnglish (US)
Pages (from-to)S63-S70
JournalExpert Review of Neurotherapeutics
Issue number6 SUPPL.
StatePublished - Nov 2005


  • Methotrexate
  • Primary central nervous system lymphoma
  • Primary intraocular lymphoma
  • Whole-brain radiation therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Primary central nervous system lymphoma'. Together they form a unique fingerprint.

Cite this